Baseline characteristics and main clinical end points of the entire GTH study cohort and the subgroup of patients with plasma samples available for immunologic analysis
| Characteristic . | GTH-AH 01/2010 population (n = 102) . | Subgroup with sample available (n = 81) . |
|---|---|---|
| Gender, n (%) | ||
| Female | 43 (42) | 35 (43) |
| Male | 59 (58) | 46 (57) |
| Underlying disorder, n (%) | ||
| None/idiopathic | 68 (67) | 53 (65) |
| Autoimmunity | 20 (20) | 14 (17) |
| Malignancy | 13 (13) | 9 (11) |
| Pregnancy | 5 (5) | 5 (6) |
| WHO-PS, n (%) | ||
| 0 | 15 (15) | 13 (16) |
| 1 | 26 (25) | 19 (23) |
| 2 | 23 (23) | 18 (22) |
| 3 | 22 (22) | 16 (20) |
| 4 | 15 (15) | 15 (19) |
| 5 | 1 (1) | 0 (0) |
| Age (y), median (IQR) | 74 (61-81) | 74 (62-81) |
| FVIII activity (IU/dL), median (IQR) | 1.4 (<1-3.9) | 1.0 (<1-3.0) |
| FVIII inhibitor concentration (BU/mL), median (IQR) | 19 (7.5-71) | 19 (7.5-71) |
| Partial remission | ||
| Achieved, n (%) | 85 (83) | 70 (86) |
| Time (days), median (IQR) | 30 (19-51) | 30 (18-50) |
| Complete remission | ||
| Achieved, n (%) | 62 (61) | 52 (65) |
| Time (days), median (IQR) | 69 (48-102) | 69 (50-98) |
| Characteristic . | GTH-AH 01/2010 population (n = 102) . | Subgroup with sample available (n = 81) . |
|---|---|---|
| Gender, n (%) | ||
| Female | 43 (42) | 35 (43) |
| Male | 59 (58) | 46 (57) |
| Underlying disorder, n (%) | ||
| None/idiopathic | 68 (67) | 53 (65) |
| Autoimmunity | 20 (20) | 14 (17) |
| Malignancy | 13 (13) | 9 (11) |
| Pregnancy | 5 (5) | 5 (6) |
| WHO-PS, n (%) | ||
| 0 | 15 (15) | 13 (16) |
| 1 | 26 (25) | 19 (23) |
| 2 | 23 (23) | 18 (22) |
| 3 | 22 (22) | 16 (20) |
| 4 | 15 (15) | 15 (19) |
| 5 | 1 (1) | 0 (0) |
| Age (y), median (IQR) | 74 (61-81) | 74 (62-81) |
| FVIII activity (IU/dL), median (IQR) | 1.4 (<1-3.9) | 1.0 (<1-3.0) |
| FVIII inhibitor concentration (BU/mL), median (IQR) | 19 (7.5-71) | 19 (7.5-71) |
| Partial remission | ||
| Achieved, n (%) | 85 (83) | 70 (86) |
| Time (days), median (IQR) | 30 (19-51) | 30 (18-50) |
| Complete remission | ||
| Achieved, n (%) | 62 (61) | 52 (65) |
| Time (days), median (IQR) | 69 (48-102) | 69 (50-98) |
IQR, interquartile range.